Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Mobile Screening Draws a Crowd

November 8th 2016

One group of oncologists has found a way to generate more business while at the same time addressing the unwillingness of people to come for screening.

The OCM Is Both Good and Questionable

November 7th 2016

The OCM program is a good start on a path that is as rough as it gets in our healthcare system that needs reform, which can't come from legislation such as Obamacare.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

November 7th 2016

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Experts Say ICD-10 Codes Don't Go Far Enough

November 4th 2016

When CMS switched from ICD-9 to ICD-10 last year, the new diagnosis classification list allowed coders to translate additional elements of doctors’ language to billers’ language. However, some coders would like to see that vocabulary expand further, particularly in the area of comorbidities and complications.

FDA Submission Completed for Niraparib in Ovarian Cancer

November 2nd 2016

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

IDO Inhibitors for Melanoma

October 31st 2016

Emerging Immunotherapy Combinations for Melanoma

October 31st 2016

Looking to the Future of Melanoma

October 31st 2016

Sequencing Strategies for Recurrent/Refractory Melanoma

October 31st 2016

Treatment Beyond Melanoma Progression

October 31st 2016

Abscopal Effect and Pseudoprogression in Melanoma

October 31st 2016

Single vs Dual Checkpoint Inhibition in Melanoma

October 31st 2016

Questions About Sequencing in BRAF-Mutant Melanoma

October 31st 2016

Dual-Targeted Therapy for BRAF-Mutant Melanoma

October 31st 2016

Risk Stratification for Advanced Melanoma

October 31st 2016

Neoadjuvant Therapy for Melanoma

October 31st 2016

Adjuvant PD-(L)1 Inhibitors for Melanoma

October 31st 2016

Adjuvant Therapy for Melanoma

October 31st 2016

Surgical Management of Locoregional Melanoma

October 31st 2016

FDA Grants Brigatinib Priority Review for ALK-Positive NSCLC

October 31st 2016

The FDA has has granted a priority review to a new drug application for brigatinib for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.